Eikon Therapeutics, Inc. (EIKN) P/E ratio
There is no P/E ratio history on record here for Eikon Therapeutics, Inc. (EIKN). Figures as of 18 Nov 2026, 11:55 UTC, from Yahoo Finance.
Figures as of . Statements from Yahoo Finance. Figures, not advice.
Not enough data
A history of P/E ratio needs at least 3 fiscal years; none is on record here for Eikon Therapeutics, Inc.. Nothing is estimated to fill the gap. What is on record is in the table below.
Eikon Therapeutics, Inc. P/E ratio, year by year
| Fiscal year | P/E ratio | Change | Year ended | Diluted EPS |
|---|---|---|---|---|
| 2025 | — | — | -$6.18 | |
| 2024 | — | — | -$7.45 | |
| 2023 | — | — | -$7.40 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
How to read it
It is the number of years of current profit the price pays for — a high figure means investors expect growth, and it is best judged against the company's own history.
Eikon Therapeutics, Inc., figure by figure
- Eikon Therapeutics, Inc. market cap
- Eikon Therapeutics, Inc. revenue
- Eikon Therapeutics, Inc. earnings
- Eikon Therapeutics, Inc. earnings per share (EPS)
- Eikon Therapeutics, Inc. P/S ratio
- Eikon Therapeutics, Inc. P/B ratio
- Eikon Therapeutics, Inc. free cash flow
- Eikon Therapeutics, Inc. operating margin
- Eikon Therapeutics, Inc. dividend
- Eikon Therapeutics, Inc. shares outstanding
- Eikon Therapeutics, Inc. total debt
- Eikon Therapeutics, Inc. cash on hand
- Eikon Therapeutics, Inc. total assets
- Eikon Therapeutics, Inc. return on equity (ROE)
- Eikon Therapeutics, Inc. return on invested capital (ROIC)
Eikon Therapeutics, Inc. (EIKN) overview: price, valuation and scorecard
Eikon Therapeutics, Inc. P/E ratio: questions and answers
How is Eikon Therapeutics, Inc.'s P/E ratio calculated?
The P/E ratio is the share price divided by earnings per share: for past years this page divides the closing price for the month each fiscal year ended in by that year's diluted earnings per share, and a year with a loss has no P/E.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/E ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- PEG ratio: P/E adjusted for growth, and its limits
The PEG ratio is a stock's P/E divided by its expected yearly earnings growth in percent. A P/E of 20 with 10% expected growth gives a PEG of 2; with 20% growth, a PEG of 1. A PEG near 1 is the traditional rough mark of a fair price, but the growth figure is a forecast and often wrong.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Eikon Therapeutics, Inc. (EIKN) P/E ratio”, data as of 18 November 2026. https://funkfolio.com/stock/EIKN/pe-ratio
Underlying data: Yahoo Finance.